CompletedNCT00791284
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
Medication studyAges 18–75Schizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00791284
- Official title
Show the full official title
Pharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Intermediate release (IR) Paliperidone.
Who was this study for?
Listed age limits: 18 years to 75 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia